Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalation of pAlliative Radiotherapy With Anti-PD1 Antibody Pembrolizumab in Thoracic Tumours

NCT02587455 is registered in ClinicalTrials.gov with Royal Marsden NHS Foundation Trust as lead sponsor.

NCT NCT02587455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02587455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalation of pAlliative Radiotherapy With Anti-PD1 Antibody Pembrolizumab in Thoracic Tumours
Lead sponsor
Royal Marsden NHS Foundation Trust
Phase
Phase 1
Overall status
Completed
Start date
June 24, 2016
Completion date
August 20, 2021
Enrollment
24 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

thoracic tumours